Shuster Jerrica E, Bleske Barry E, Dorsch Michael P
University of Michigan Hospitals and Health Centers, Ann Arbor, MI 48109, USA.
Vasc Health Risk Manag. 2012;8:381-7. doi: 10.2147/VHRM.S22583. Epub 2012 Jun 13.
Azilsartan-chlorthalidone fixed combination is a new drug in the management of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing for years. The combination is unique because it is the first to partner an ARB with this, possibly more effective, diuretic. This review will address trials involving both components of this drug, as well as phase III trials involving the fixed-combination product. The article will also discuss the benefit of combination therapy in the treatment of hypertension.
阿齐沙坦-氯噻酮固定复方制剂是高血压治疗领域的一种新药。已证明阿齐沙坦比其他血管紧张素受体阻滞剂（ARB）具有更强的降压作用，并且关于氯噻酮优于氢氯噻嗪的争论已经持续多年。这种复方制剂很独特，因为它是首个将ARB与这种可能更有效的利尿剂联合使用的药物。本综述将探讨涉及该药物两种成分的试验，以及涉及该固定复方制剂的III期试验。本文还将讨论联合治疗在高血压治疗中的益处。
